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Abstract
Background—Vaginal SHIVSF162P3 acquisition in pigtail macaques (Macaca nemestrina) is 
dependent on time point during the menstrual cycle. Susceptibility is higher around menstruation 
and lower at ovulation in mid cycle. This complicates design of repeat low-dose (RLD) SHIV 
exposure studies because virus challenges given during low susceptibility periods have lower 
chances to infect. To account for fluctuating susceptibility, we analyzed menstrual cycles rather 
than exposures until infection following virus challenges.
Findings—We first re-analyzed infection data of 41 macaques receiving placebo or no treatment 
during once (n=18) or twice (n=23) weekly virus exposures. The same number of cycles was 
required for infection with either challenge frequency, while it took a median 4 or 6 challenges for 
once or twice weekly exposures, respectively. More virus challenges to infection likely reflect 
frequent unsuccessful exposures in frequently exposed animals. When re-analyzing two previously 
reported biomedical HIV intervention studies, we found 1% Tenofovir gel was 74 or 86 % 
efficacious based on cycles or exposures (p = 0.019 or = 0.003, respectively, Fisher’s exact test), 
while 1% Raltegravir gel was 84 or 89 % efficacious, respectively (p = 0.047 or = 0.031).
Conclusions—Evaluating number of menstrual cycles rather than exposures until infection can 
account for varying susceptibility during the menstrual cycle. Our observations have implications 
for future study designs such as planning frequency of virus exposures. Menstrual cycle analysis 
may also avoid potential over-estimation of efficacy against vaginal challenges during low 
susceptibility periods in the cycle that are unlikely to cause infection.
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The repeat low- dose (RLD) virus exposure model has been developed to test HIV 
prevention strategies in macaques 1, 2. This experimental approach models physiologic 
sexual HIV exposures which often do not cause infection after a single exposure 3. Unlike 
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the conventional single-high dose model, it allows experimental detection of efficacious 
HIV preventions when high doses may overwhelm the interventions. This model also 
enables use of small macaque groups by evaluating outcomes of each repeated virus 
exposure 4-6, assuming that each virus exposure can lead to infection.
For experiments with vaginal RLD SHIV exposures 2, 7, our group uses pigtail macaques 
(Macaca nemestrina) because they can easily be vaginally infected, have stable year-round 
median 32 -day menstrual cycles 8, 9, and are of favorable size for gynecological exams 10. 
However, their susceptibility to vaginal SHIV infection fluctuates during the menstrual 
cycle, peaking one week prior to and one week after onset of menstruation 9, 11. This 
complicates the analysis of the number of exposures required for infection, as repeated 
exposures during the cycle thus have unequal chances to infect and depend on exposure 
initiation time within the cycle. As an alternative, we have refined the RLD model for 
evaluating biomedical intervention studies, by reporting the number of menstrual cycles 
required for infection 12-15. To accomplish this, we have since so far used calendar months, 
28-day time segments, or actual menstrual cycle analysis with differing cycle lengths for 
each animal 12-15, and have attempted to initiate virus exposures at select menstrual cycle 
phases 14. We here report our experiences, and provide an in-depth description of our 
analysis methods.
To illustrate effects of two different analysis methods, we provide a side-by-side comparison 
of the number of exposures until infection occurred and of cycles to infection. In Fig. 1, we 
plotted Kaplan-Meier infection survival curves of 41 SHIVSF162P3-infected female control 
animals. Adult female pigtail macaques were infected at CDC according to humane care 
guidelines 16 and with IACUC (Institutional Animal Care and Use Committee) approval. 
They were control- or placebo-treated animals from various prevention trials 2, 7, 12, 13, 17 
with different study designs; their menstrual cycle determination, infection and susceptibility 
during the cycle has been reported 9, 11 and tabulated11 . Macaques received one (n=18) or 
two (n=23) low-dose SHIVSF162P3 exposures 18 (10-50 TCID50) per week for up to 14-20 
exposures, in accordance with their original study designs 2, 7, 12, 13, 17. Exposures started 
randomly within the menstrual cycle, continued throughout menstruation, and were stopped 
when animals became SHIV-positive. The infecting virus exposure was identified as the 
challenge given seven days prior to SHIV detection of at least 50 copies/mL. To determine 
the number of menstrual cycles required for infection, we applied 28-day periods from the 
start of challenges, regardless of actual cycle data. Logistical hurdles prevented the 
implementation of 32- day periods because resulting eight-day intervals between virus 
challenges meant animal procedures would fall on different week days each week, 
conflicting with operational procedures in our animal facility. Alternatively, if challenges 
occurred on the same weekday each week, some 32-day periods would have 4, others 5 virus 
exposures, complicating comparisons of infections during menstrual cycles. For one 
exposure per week and using 28-day periods, SHIV infection in the first, second, third and 
fourth cycle meant macaques received 1-4, 5-8, 9-12, 13-16 exposures before their first 
positive viral load, respectively. Uninfected animals were evaluated at completed cycles, 
even if further exposures happened in additional, but incomplete cycles. For example, a 
macaque remaining uninfected after 14 weekly challenges completed three cycles but not 
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four, and received two superfluous challenges that were not evaluated. For two exposures 
per week, infection in first, second, or third cycle meant macaques received 1-8, 9-16, or 
17-24 exposures before their first positive viral load, respectively. Kaplan-Meier survival 
graphs were constructed and analyzed with GraphPad Prism5.03 (San Diego, CA), also used 
for Fisher’s exact, two-tailed outcome comparisons.
When we separately analyzed macaques receiving one or two challenges per week, we 
found four and six median numbers of exposures were required for infection, respectively 
(Fig. 1A). This difference was not statistically different (log-rank test, p=0.19). Infection 
rates (infections/ number of exposures) were also not significantly affected by challenge 
frequency (p=0.271, Fisher’s exact test). Three macaques remained uninfected after 14 
exposures. Although the difference in challenges required for infection was not statistically 
significant for the two challenge frequencies, the observation is consistent with expectations 
due to varying susceptibility during the cycle. If a portion of animals started challenges in a 
low susceptibility period, more unsuccessful exposures will happen in twice-weekly exposed 
animals compared to once-weekly exposed animals until a high susceptibility period is 
reached.
The survival curves for menstrual cycle analysis for macaques receiving one or two 
challenges per week were strikingly similar for the two frequencies (Fig. 1B; log-rank test, 
p=0.51). One median cycle was required for infection, regardless of exposure frequency. 
Thirty-nine percent of the macaques remained uninfected after the first menstrual cycle of 
challenges for each frequency. These findings indicate that exposing animals twice per week 
is not advantageous over once per week. This new observation has implications for future 
study designs with reduced virus challenge frequency, potentially improving animal health 
due to reduced anesthesia frequency and lowering virus needs and animal technician time.
We next conducted a re-analysis of two previously published HIV intervention studies 15, 19, 
and provide a side-by-side evaluation of the number of exposures until infection occurred 
(Fig. 2, left panels), compared to the published evaluation using cycles to infection (Fig. 2, 
right panels). Only partially efficacious interventions were re-analyzed, because the 
completely protective interventions we have reported 7, 12, 13 are fully efficacious, regardless 
of the analysis method. The first intervention included a 1% Tenofovir (TFV) gel modality 
in which six macaques received vaginal gel and were challenged with virus 30 minutes and 
72 hours later 19, and compared to ten placebo-treated animals. A second intervention had 
one percent Raltegravir (RAL) gel given three hours after SHIV exposure as post-exposure 
prophylaxis 15 (6 experimental and 4 placebo-treated macaques). Efficacy of preventing 
infection was calculated as Efficacy (%) = 1 - (Pi/Pc) with P (infection rate; i=intervention, 
c=control) = number of infections/ number of challenges or cycles.
For the first intervention study evaluating efficacy of 1% TFV gel to prevent vaginal 
SHIVSF162P3 infection 19, analysis of exposures to infection showed 86% efficacy (Fig. 1A, 
left panel, p=0.003, Fisher’s exact test) compared to 74% efficacy (Fig. 1A, right panel, 
p=0.019) when efficacy measurements were analyzed by number of exposures or cycles to 
infection, respectively. Likewise, for 1% RAL gel 15, efficacy was calculated at 89% or 84% 
(Fig. 1B, p=0.031 or p=0.047, respectively, by Fisher’s exact test). Thus, the two 
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interventions found partially efficacious with cycle analysis were also partially efficacious 
using exposure number as the analysis method. In both examples, menstrual cycle analysis 
yielded a slightly lower efficacy value. However, this observation could not be supported by 
statistical comparisons, as only two example trial results were available. Larger sample sizes 
and additional statistical analyses might be able to ascertain this observation with statistical 
significance if and when more trial results become available. It is possible – but not proven 
by our observations - that analysis by exposure number may overestimate efficacy, 
potentially because unsuccessful virus challenges during low susceptibility periods 
contribute to efficacy calculations. This is particularly true for protected animals who 
survive many challenges uninfected, while most control animals become infected as soon as 
a high susceptibility period is reached. Therefore, low susceptibility periods may affect 
efficacy calculations for intervention animals more than control animals when analyses are 
based on exposure numbers.
Choice of analysis method by number of cycles or exposures likely matters most when 
experimental groups are comprised of animals that are not distributed equally in all possible 
parts of their cycles at study start, i.e., have some degree of synchronicity. Then it is possible 
that animals of one group but not the other start exposures in low susceptibility periods. It is 
difficult to distribute animals equally into study groups according to cycle status. 
Progesterone data are easiest to interpret in retrospect when longitudinal trajectories are 
available, i.e., not at study start. We have also encountered individual animals with 
consistent cycling patterns until experimentation started, only to find that the stresses of 
increased animal handling and fasting for anesthesia unpredictably affected cycles. We 
therefore suggest it is prudent to choose analysis by assessing menstrual cycles post hoc 
rather than anticipating menstrual cycles before study start.
Menstrual cycle analysis solves the problem of lacking cycle synchronicity at study start, but 
it does not eliminate the problem that animals may be cycling irregularly, and are unequally 
distributed in study groups. For example, if in a study comparing interventions, animals in 
one group are regularly cycling but in the other group animals are not cycling or have 
irregular cycles, their proportions of time in periods of high susceptibility will vary and 
affect interpretation of intervention efficacy. However, this biological issue of differing 
susceptibility confounds both analysis types, and is not solved by switching analysis 
method.
When we implemented these methods a few issues arose regarding experimental design. We 
have since chosen to use 28-day increments rather than actual, measured cycle lengths as 
previously explored 14. This had resulted in varying number of virus challenges per cycle 
due to short or long cycles. Not relying on actual cycle length determination also avoids 
lengthy cycle monitoring before study start to determine day 1 of each cycle, and exclusion 
of animals with incomplete cycle information, saving time and allowing all challenge data to 
be used. We prefer to use 28-day analysis units over the median 32 days of pigtail cycles 8, 9 
to allow convenient once-weekly exposures on the same week day in each unit, as is 
desirable for workflow in our animal facility. We acknowledge the effect of the four-day 
difference from median 32-day cycle length has not yet been fully analyzed. For animals 
remaining uninfected or protected from infection, we have started to only analyze completed 
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28-day units, because partial cycles may have started during low susceptibility periods 
without substantial chance of infection. Thus, we now usually plan experiments in multiples 
of 28-day intervals, i.e., 4, 8, 12, 16, or 20 exposures once per week. For example, the 
uninfected macaque after 14 weekly challenges shown in Fig. 1 received two superfluous 
challenges that were not evaluated because the fourth cycle was incomplete. Also, exposure 
interruptions are difficult to interpret with both analysis methods, as animals may miss 
susceptible periods. For example, one previously evaluated macaque (macaque 303, 11) was 
not included in Fig. 1 because virus challenges were interrupted for three weeks due to a 
holiday. If unavoidable, a full 28-day interruption can be considered, regardless of analysis 
method.
A study limitation was that we did not evaluate further reduction of virus challenge 
frequency beyond once per week. In addition, exploring implications for statistical power of 
RLD studies will be helpful, as will statistical simulations of cycle synchronicity in animal 
groups of different sizes. This was not the focus of this report on our practical experiences 
with RLD studies.
Alternatives to menstrual cycle analysis are to synchronize macaques before study start, e.g., 
with birth control pills as we have previously done 20, or to start virus challenges at the same 
cycle time point in each animal, also previously reported 14. These methods are laborious 
and time intensive, susceptible to erroneous menstrual cycle judgment and to unpredictable 
cycling changes during experimentation.
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Figure 1. Comparison of analysis methods for data from 41 untreated or Placebo-treated control 
macaques
Forty-one pigtail macaques were repeatedly exposed to intra-vaginal SHIVSF162P3 with 
random start time relative to their menstrual cycle (previously summarized 11). A. Kaplan-
Meier survival graph displays the percentage of macaques remaining uninfected after the 
indicated exposures to infection. Three animals remained uninfected after 14 exposures, as 
indicated by asterisks. One animal was in the group receiving one exposure per week, the 
other two were in the group receiving two exposures per week. B. Kaplan-Meier survival 
graph displays the percentage of macaques that remained uninfected throughout menstrual 
cycles with virus exposures. Menstrual cycle here is defined as a 28-day interval.
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Figure 2. Comparison of analysis methods for intervention data
The graphs show Kaplan-Meier survival graphs to plot the percentage of pigtail macaques 
remaining uninfected after number of vaginal SHIVSF162P3 challenges received (left panels) 
or after number of menstrual cycles with virus challenges (right panels). A. Data are from a 
pre-exposure prophylaxis (PrEP) trial using 1% Tenofovir gel 19. B. Data are from a post-
exposure prophylaxis (PEP) trial with Raltegravir gel 15. P values are calculated by Fisher’s 
exact test.
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